Valence8 US LP Purchases New Shares in argenx SE (NASDAQ:ARGX)

Valence8 US LP acquired a new position in argenx SE (NASDAQ:ARGX) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 953 shares of the company’s stock, valued at approximately $517,000. argenx makes up approximately 0.2% of Valence8 US LP’s investment portfolio, making the stock its 20th biggest holding.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ARGX. Blue Trust Inc. increased its stake in shares of argenx by 620.0% in the 2nd quarter. Blue Trust Inc. now owns 72 shares of the company’s stock worth $28,000 after acquiring an additional 62 shares in the last quarter. J.Safra Asset Management Corp lifted its holdings in shares of argenx by 590.0% during the second quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock valued at $30,000 after purchasing an additional 59 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of argenx by 51.3% during the second quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock valued at $51,000 after purchasing an additional 40 shares during the last quarter. Point72 Hong Kong Ltd bought a new stake in shares of argenx in the 2nd quarter worth approximately $76,000. Finally, Cromwell Holdings LLC grew its stake in shares of argenx by 73.3% in the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock worth $85,000 after buying an additional 66 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Analyst Upgrades and Downgrades

ARGX has been the subject of a number of recent research reports. Evercore ISI lifted their price objective on argenx from $675.00 to $706.00 and gave the company an “outperform” rating in a research note on Thursday. Truist Financial raised their price objective on shares of argenx from $540.00 to $660.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. William Blair upgraded shares of argenx from a “market perform” rating to an “outperform” rating in a research note on Friday, November 1st. Barclays upgraded shares of argenx from an “equal weight” rating to an “overweight” rating in a report on Tuesday, August 6th. Finally, Robert W. Baird lowered shares of argenx from an “outperform” rating to a “neutral” rating and boosted their price objective for the stock from $515.00 to $650.00 in a report on Friday, November 1st. Three research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $630.42.

argenx Trading Up 1.4 %

Shares of NASDAQ ARGX opened at $600.35 on Friday. argenx SE has a 12-month low of $327.73 and a 12-month high of $611.22. The firm has a market capitalization of $35.90 billion, a price-to-earnings ratio of -682.21 and a beta of 0.61. The firm has a 50 day moving average of $555.08 and a 200 day moving average of $485.94.

argenx (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.10 by $1.29. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The firm had revenue of $588.88 million during the quarter, compared to the consensus estimate of $543.29 million. During the same quarter in the previous year, the firm posted ($1.25) EPS. Sell-side analysts predict that argenx SE will post 2.2 EPS for the current year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.